A contract research team can receive a vial with a certificate that reads ≥99% purity and still be holding an unknown. That is not a criticism of the analytical method; it is a limit of what a single percentage can prove. Purity describes how much of the detected material sits in the main peak. Identity testing asks a different question: is that main peak the compound the label claims? For laboratories working with research-use-only materials, the two pieces of evidence have to travel together. Research Sciences, a UK supplier of research-use-only peptides and laboratory accessories, describes its CoAs as covering both purity and identity, alongside contaminant screening. That framing is useful because it keeps the contract research team focused on the batch document rather than a headline number. None of these materials are for human or veterinary use.
Purity measures proportion, not provenance
A purity percentage from HPLC is an area-normalisation exercise. The software reports the main peak as a proportion of the total integrated signal. A figure of 99% can mean the main peak is large and the minor peaks are small, but it does not tell the reviewer what the main peak is. The same number can appear for the correct peptide, a closely related sequence, a scrambled variant, or a sample that has been mixed up before vialling. For an in-vitro assay, that distinction matters. A contract research team may be comparing a test group against a vehicle control, running a receptor-binding study, or generating data for a client. If the identity is wrong, the purity percentage becomes a precise answer to the wrong question.
This is why identity testing has to sit beside the purity percentage. Identity testing, as documented on the batch CoA, supports the claim that the material matches the expected compound. Research Sciences states that every compound includes a CoA for purity and identity, and that submitted samples are evaluated for purity, identity, heavy metals and endotoxin. The exact methods and results belong on the batch document; researchers should open that document rather than infer identity from a website headline. The homepage currently publishes lines such as “≥99% Verified Purity” and “UK Research Materials Over 99.1% Purity”. Those are the shop’s published figures at the time of writing and should be reconfirmed on the live site and, where relevant, on the batch CoA.
Why a high percentage can hide a low-information result
Consider a contract laboratory that receives two vials on the same day. Both CoAs show a main peak above 99%. One vial is the expected peptide; the other is a sequence that differs by a single residue. A purity figure alone cannot separate them. An identity check can. The same logic applies when a restocked product carries the same Internal Test Reference (ITR) as earlier stock. The ITR links to associated sample testing reports, but it does not confirm that separate deliveries come from the same production lot or that they have had separate independent testing. Vial cap colours and other packaging may vary; cap colour is not an indicator of identity, analytical quality or manufacturing origin. For a contract research team, these are not administrative details. They are the difference between a reproducible assay and an unexplained outlier.
Where identity testing sits in the contract research workflow
Identity testing is most useful when it is built into the receiving workflow rather than treated as a retrospective check. A UK contract research team can start by matching the vial label reference — the SKU code and expiry date, for example BPC10-03/27 — to the corresponding CoA. That reference should be quoted when contacting the supplier about documentation. The CoA should then be reviewed for both identity and purity, not just the percentage. If the team is sourcing Uk peptides, the batch CoA is the first document to open after receipt and the last document to cite before releasing material into an in-vitro study. The team should check that the compound name, batch reference and test results align with the order, and that the purity figure is read alongside the identity confirmation. This is also the point to confirm storage conditions: lyophilised peptides are typically stored at −20°C or below, sealed with desiccant, protected from moisture, heat and light, with reconstituted material held at 2–8°C for short-term laboratory use.
The workflow also needs a place for contaminant screening. Research Sciences describes full-spectrum testing that includes heavy metals and endotoxin evaluation alongside purity and identity. For the contract research team, those results answer a different question from identity: they address what else may be present. The identity result addresses what the main material is. Neither result replaces the other, and neither is replaced by a headline purity percentage. A practical receiving checklist can therefore have separate lines for identity confirmation, purity result, contaminant screening, label-to-CoA matching, and storage entry. When a restock arrives, the team should not assume that a shared ITR means a shared production lot. The ITR is a link to associated sample testing reports; it is not a statement that separate deliveries have had separate independent testing. That distinction belongs in the receiving record.
Documentation that supports both identity and purity
Contract research teams are often asked to demonstrate that materials were fit for purpose at the time of use. That demonstration is stronger when the batch CoA is treated as a living document rather than a one-off attachment. The CoA should show the identity result and the purity result together, and the team should be able to trace the vial label reference back to that document. Research Sciences states that its CoAs are linked to supported products and that every compound includes a CoA for purity and identity. The shop also describes final verification and quality checks in the UK before release. Those are the shop’s stated processes; the researcher’s task is to verify the actual batch document that accompanies the material, not to rely on a general description.
Published delivery and order figures should be read in the same spirit. The homepage currently lists “3,000+ UK Orders” and “24hr UK Delivery”, while the FAQs describe next-working-day dispatch and Royal Mail Tracked 24 as an estimate rather than a guarantee. Those details are relevant to planning, but they are not analytical evidence. For the contract research team, the evidence hierarchy is clear: the batch CoA for identity and purity, the label reference for traceability, the storage record for handling, and the receiving checklist for internal audit. If a purity percentage is quoted in a client report, it should be accompanied by the identity confirmation from the same batch CoA. Otherwise the report gives a number without a subject.
Reconstitution and handling should stay inside the in-vitro laboratory workflow. Research Sciences describes a free peptide reconstitution calculator for laboratory research use only, covering mg, mcg, mL, U-100 and U-50 syringe scales with optional IU conversions when a conversion factor is known. It must not be used for human or veterinary dosing. Materials are not for human or veterinary use, and they are not medicines, medical devices, injectables, treatments or food supplements under UK law. The contract research team should work in a clean environment, allow vials to reach room temperature before opening, remove only the amount required for the experiment, and avoid repeated freeze–thaw cycles. The batch CoA, the label reference and the storage record should all be retrievable when the assay is reviewed.
